ClinicalTrials.gg
BiologicalDrug

Sargramostim clinical trials

Also written BAY86-5326 and DRG-0012.

studies test it
142
open now
3
in phase 3
15
first study started
1993

How each study uses sargramostim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sargramostim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
5 Mar 1991 · LEUKINE · BLA 103362 (FDA, Drugs@FDA)
European Union
21 Aug 2025 · Imreplys · EMEA/H/C/006411 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

sargramostim
119
Leukine
49
GM-CSF
29
Prokine
18
rhu GM-CFS
8

Development codes

BAY86-5326
8
DRG-0012
7
rhu-GM-CSF
2
NSC-613795
1

Studies by the year they started

138 studies that test it; most in 2004 (13)

Studies that test sargramostim, by start year
YearStudies
19931
19953
19963
19974
19984
19997
200011
20018
20027
20037
200413
20055
200611
20075
20082
20093
20101
20114
20122
20135
20142
20154
20166
20173
20193
20206
20212
20222
20232
20242

By phase

A phase 1/2 study counts in both.

Phase 1
45
Phase 2
91
Phase 3
15
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 117

National Cancer Institute (NCI) (13) · Genzyme, a Sanofi Company (8) · University of Nebraska (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Children's Oncology Group (5) · University of Washington (4) · Partner Therapeutics, Inc. (4) · University of Colorado, Denver (4)

Often tested with

Tested in the same studies.

Cyclophosphamide (9) · Rituximab (8) · Etoposide (8) · Doxorubicin (6) · Filgrastim (6) · Vincristine (4) · Aldesleukin (4) · Carboplatin (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test sargramostim.

Studies

Open first, then newest update. How each study uses sargramostim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 142

See all 142 studies that test sargramostim →

Given beside what is tested · 88 — sargramostim is usual care or a partner of the new treatment

Showing 20 of 88.

As the comparator · 2 — what is tested is compared with sargramostim

Codes

What other systems call sargramostim · ClinicalTrials.gg INT003728

  • MeSH (NLM) C081222sargramostimConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 5TAA004E22SARGRAMOSTIMConfirmed FDA, NLM, Wikidata
  • RxNorm 69634Confirmed FDA, Wikidata
  • Wikidata Q3950557sargramostimConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1492SargramostimOne source FDA
  • DrugBank DB00020One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.